For The Biome Delivers Highly Anticipated Formulation of Cistus Incanus to North American Market, Mediterranean Herb Clinically Proven to Strengthen Immune Response in 2 Hours
30 mars 2021 08h50 HE | For The Biome
DUMMERSTON, VT, March 30, 2021 (GLOBE NEWSWIRE) -- For The Biome, founded by industry innovator and master herbalist Paul Schulick, has launched Immune Therapy Cistus+ Infusion, a groundbreaking...
ritter.jpg
Ritter Pharmaceuticals, Inc. Announces Expected Closing of Merger Transaction with Qualigen, Inc.
22 mai 2020 12h35 HE | Ritter Pharmaceuticals, Inc.
LOS ANGELES, May 22, 2020 (GLOBE NEWSWIRE) -- Ritter Pharmaceuticals, Inc. (Nasdaq: RTTR) (“Ritter Pharmaceuticals”, “Ritter” or the “Company”), today announced that its pending merger transaction...
ritter.jpg
Ritter Pharmaceuticals, Inc. Announces Form S-4 Registration Statement Declared Effective by SEC
16 avr. 2020 14h07 HE | Ritter Pharmaceuticals, Inc.
Special Meeting of Ritter Pharmaceuticals, Inc. Stockholders to Vote on Proposed Merger Scheduled for May 14, 2020 LOS ANGELES , April 16, 2020 (GLOBE NEWSWIRE) -- Ritter Pharmaceuticals, Inc....
ritter.jpg
Ritter Pharmaceuticals Reports Financial Results for the Fourth Quarter and Year Ended December 31, 2019
31 mars 2020 17h27 HE | Ritter Pharmaceuticals, Inc.
Definitive merger agreement with Qualigen, Inc. announced in January 2020 LOS ANGELES, March 31, 2020 (GLOBE NEWSWIRE) -- Ritter Pharmaceuticals, Inc. (Nasdaq: RTTR) (“Ritter Pharmaceuticals”,...
ritter.jpg
Ritter Pharmaceuticals, Inc. and Qualigen, Inc. Announce Merger Agreement
21 janv. 2020 09h15 HE | Ritter Pharmaceuticals, Inc.
Transaction to Create a Nasdaq-listed Biotechnology Company Focused on Advancing Qualigen’s Cancer and Infectious Disease Therapeutic Development Programs LOS ANGELES, Jan. 21, 2020 (GLOBE...
ritter.jpg
Ritter Pharmaceuticals Reports Financial Results for the Three and Nine Months Ended September 30, 2019 and Provides Business Update
13 nov. 2019 19h35 HE | Ritter Pharmaceuticals, Inc.
LOS ANGELES, Nov. 13, 2019 (GLOBE NEWSWIRE) -- Ritter Pharmaceuticals, Inc. (Nasdaq: RTTR) (“Ritter Pharmaceuticals” or the “Company”), a developer of therapeutic products that modulate the gut...
ritter.jpg
Ritter Pharmaceuticals Announces Appointment of Andrew J. Ritter as Chief Executive Officer
27 juin 2018 07h05 HE | Ritter Pharmaceuticals, Inc.
LOS ANGELES, June 27, 2018 (GLOBE NEWSWIRE) -- Ritter Pharmaceuticals, Inc. (Nasdaq: RTTR) (“Ritter Pharmaceuticals” or the “Company”), a developer of innovative therapeutic products that modulate...
Qualigen Therapeutics, Inc. - LOGO.jpg
Ritter Pharmaceuticals, Inc.’s Board Approves 1-for-10 Reverse Stock Split
01 mars 2018 16h20 HE | Ritter Pharmaceuticals, Inc.
Los Angeles, California, March 01, 2018 (GLOBE NEWSWIRE) -- Ritter Pharmaceuticals, Inc. (NASDAQ: RTTR) (“Ritter Pharmaceuticals” or the “Company”), a leading developer of novel therapeutic products...
Qualigen Therapeutics, Inc. - LOGO.jpg
Ritter Pharmaceuticals Reports Third Quarter 2017 Financial Results and Provides Business Update
31 oct. 2017 06h45 HE | Ritter Pharmaceuticals, Inc.
LOS ANGELES, Oct. 31, 2017 (GLOBE NEWSWIRE) -- Ritter Pharmaceuticals, Inc. (NASDAQ:RTTR) (“Ritter Pharmaceuticals” or the “Company”), a pharmaceutical company developing novel therapeutic products...
Qualigen Therapeutics, Inc. - LOGO.jpg
Ritter Pharmaceuticals, Inc. Raises $23 Million to Fund Initiation of Its Phase 3 Clinical Program in Lactose Intolerance
03 oct. 2017 12h00 HE | Ritter Pharmaceuticals
Los Angeles, California,, Oct. 03, 2017 (GLOBE NEWSWIRE) -- Ritter Pharmaceuticals, Inc. (NASDAQ: RTTR) (“Ritter Pharmaceuticals” or the “Company”), a leading developer of novel therapeutic products...